MARKET WIREYahoo • 2d ago
3 Promising Genomics Stocks to Add to Your Portfolio NowGenomics and synthetic biology are transforming healthcare through precision medicine and gene editing, putting ILMN, QURE and TXG in focus as the markets expand.
Why QURE Stock advanced +1.32% Today — RQD Quant Desk Flash
$25.30 +1.32% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $25.31
uniQure N.V. (QURE) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D+ • SELL / AVOID
Cap $1.75B
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $25.31 (+0.05%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY • 50.1% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D+
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D- · Rk C+
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for QURE)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (52/100 Composite)
🔍 WHY QURE SCORES 52/100 (D+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Whale & Options Positioning+14/20 pts (27% of score)
20D Institutional Volume Accumulation (±12.5% realized swing band)
▲ #2 Bullish Driver: Macro Regime Fit+14/20 pts (27% of score)
FRED Regime × Technicals: 39% of 52W Range • RSI-14 at 42.4 (NEUTRAL RANGE)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$22.59-3.6% Next Q
44
Q2 (-2Q)Grade D$21.78+3% Next Q
47
Q3 (-1Q)Grade D$22.43+12.8% Next Q
49
CurrentGrade D+$25.30-1.1% Hist 90D α
52
Trajectory: D (44) → D+ (52)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a QURE Turnaround Squeeze
While QURE currently carries a cautious 52/100 (D+) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($34.55) and Max Pain ($26.57) forces dealer call-delta covering toward $54.31.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $QURE• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “QURE Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why QURE Stock advanced +1.32% Today — RQD Quant Desk Flash
uniQure N.V. (QURE) advanced +1.32% to $25.30, trading at 39% of its 52-week range ($8.73 – $51.72). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 39% of its 52-week range ($8.73 – $51.72) with RSI-14 at 42.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $25.30 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D+ (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live QURE Headlines & Catalysts
CATALYSTYahoo • 3d ago
uniQure (QURE) Stock Could Be Overvalued Despite A Securities InvestigationuniQure shares closed at US$24.97 after a turbulent few years, and that mix of sharp swings and fresh clinical scrutiny now raises a straightforward question for investors about how the current market price lines up with
CATALYSTYahoo • 3d ago
What ClearPoint Neuro (CLPT) Said on Its Q3 Earnings CallClearPoint Neuro (NASDAQ:CLPT) reported third-quarter 2026 revenue growth of 36% as sales increased across its biologics and drug-delivery, neurosurgery navigation and therapy, and capital equipment and software business
MARKET WIREYahoo • 4d ago
uniQure to Announce Third Quarter 2026 Financial Results~ uniQure to host earnings call on Wednesday, November 4, 2026 at 8:30 a.m. ET ~LEXINGTON, Mass. and AMSTERDAM, Oct. 28, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing tran
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring QURE)
- ✓Walkthrough of QURE's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
QURE // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +26.82%📐 HORIZONTAL RANGE
2026-10-30O $25.11H $25.30L $23.56C $25.30VOL 1.88M
RES: $53.12SUP: $19.88SMA50: $34.55SMA200: $29.65
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
QURE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on QURE today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for QURE. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for QURE today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (QURE)
Health Care Rank #316 of 1016
⚔️ KLRA vs QURE Full Matrix →
1. Head-to-Head Health Care Peer Comparison (QURE vs. KLRA, NBTX, STOK, CMPS)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, uniQure N.V. (QURE) ranks #316 by composite RQD confidence (52/100, grade D+) and #281 by equity capitalization ($1.75B). Within this direct 5-issuer industry benchmark cohort, QURE leads on earnings valuation at N/A trailing P/E, while STOK leads on capital efficiency and profitability with -6.1% ROIC and — gross margin. STOK currently holds the highest overall quantitative score in the immediate peer group at 59/100 (C-) compared with QURE at 52/100 (D+).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| QURE
ACTIVE
uniQure N.V. | D+ | 52/100 | — | — | -35.0% | +1.32% | $1.75B | Benchmark Subject |
| KLRA Kailera Therapeutics Inc. | D | 50/100 | — | — | — | -0.07% | $1.74B | /klra-vs-qure → |
| NBTX Nanobiotix S.A. | D+ | 52/100 | — | — | — | -0.53% | $1.72B | /nbtx-vs-qure → |
| STOK Stoke Therapeutics Inc. | C- | 59/100 | — | — | -6.1% | -0.23% | $1.70B | /stok-vs-qure → |
| CMPS COMPASS Pathways Plc American Depository Shares | D- | 37/100 | — | — | -35.0% | -0.73% | $1.69B | /cmps-vs-qure → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001590560In its most recent audited fiscal period (FY2025, filed 2025-12-31), uniQure N.V. (QURE) reported GAAP revenue of $0 (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$199.0M, operating cash flow of -$178.0M, and free cash flow of -$178.4M (+4.1% YoY). On the balance sheet, QURE closed FY2025 with $824.9M in total assets against $49.7M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 4/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $0 | -$199.0M | -$178.0M | -$178.4M | $824.9M | $49.7M |
| FY2024 (FY) | 2024-12-31 | $0 | -$239.6M | -$182.7M | -$186.1M | $556.5M | $51.3M |
| FY2023 (FY) | 2023-12-31 | $0 | -$308.5M | -$145.9M | -$145.9M | — | — |
3. QURE Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs QURE stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, uniQure N.V. (NASDAQ: QURE) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $25.30 (+1.32% 1D, market cap $1.75B). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 14/20, Executive Insider Alignment 13/20, FRED Macro Regime Fit 14/20, and SEC Balance-Sheet Forensics 5/20. Across 1016 tracked Health Care issuers, QURE ranks #316 in composite RQD confidence.
How does QURE compare to KLRA and NBTX in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), QURE carries a Roarable D+ (52/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, KLRA (Kailera Therapeutics Inc.) holds a D grade (50/100 RQD, P/E N/A, ROIC —, cap $1.74B) and NBTX (Nanobiotix S.A.) posts a D+ grade (52/100 RQD, P/E N/A, ROIC —, cap $1.72B). Among the 5-stock peer group, QURE leads on earnings multiple (N/A) while STOK leads on capital efficiency (-6.1% ROIC).
What are the biggest fundamental strengths and SEC risk factors for QURE?
Per QURE's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001590560), uniQure N.V. generated $0 in revenue, -$199.0M in net income, and -$178.4M in free cash flow against $824.9M in total assets and $49.7M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is QURE trading relative to its 50-day, 200-day, and 52-week technical levels?
QURE last traded at $25.30 (+1.32% on volume of 1,713,465 shares), positioning the stock -26.77% below its 50-day simple moving average ($34.55) and -14.67% below its 200-day simple moving average ($29.65). Across its 52-week range of $8.73 to $51.72, QURE sits at the 38.5% percentile with a 14-day RSI of 42.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($22.14 to $28.46).
QURE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is QURE stock moving today?
Why QURE Stock advanced +1.32% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.